Physician profile
Mark A Rector
NPI 1306846993
$760.32
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $233 · 2021: $274 · 2022: $42.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $158.11 | 2019-2022 | |
| Amarin Pharma, INC. | $88.43 | 2020-2021 | |
| Pfizer INC. | $77.33 | 2019-2021 | |
| Novo Nordisk INC | $45.50 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $44.95 | 2020-2021 | |
| Dexcom, INC. | $41.64 | 2020-2021 | |
| Lilly USA, LLC | $37.07 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $31.98 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.69 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.35 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.06 | 2022 | |
| Daiichi Sankyo INC. | $22.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.46 | 2021 | |
| Medtronic Minimed, INC. | $16.04 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.22 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $12.67 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.26 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.13 | 2019 | |
| Astellas Pharma US INC | $11.24 | 2021 | |
| Gilead Sciences, INC. | $11.08 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.